Granted Patent B2

US 12,459,980 · App. 17/262,940 · Granted Nov 4, 2025

Inventors: Yuefeng Lu (Newbury Park, CA); Chunxiao Yu (Santa Barbara, CA)

Assignee: ASKGENE PHARMA, INC.

C07K14/54A61P35/00C07K14/7155C07K16/2818A61K38/00C07K2319/30

Abstract

Claims (39)

1 . A prodrug comprising a human IL-21 agonist polypeptide, a masking moiety, and a carrier moiety, wherein the human IL-21 agonist polypeptide comprises SEQ ID NO: 1, or comprise an amino acid sequence identical to SEQ ID NO: 1 but for one or more mutations selected from D18A/K, Q19K, and E109R (numbering according to SEQ ID NO: 1), the masking moiety comprises consists of an extracellular domain (ECD) of a human IL-21 receptor α or γ subunit,

the human IL-21 agonist polypeptide is fused to the carrier moiety, and

the masking moiety is fused to the human IL-21 agonist polypeptide or to the carrier moiety through a cleavable peptide linker.

2 . The prodrug of claim 1 , wherein the IL- 21 agonist polypeptide has an amino acid sequence selected from SEQ ID NO: 2, 3, 4, and 5.

3 . The prodrug of claim 1 , wherein the IL-21 receptor subunit ECD comprises SEQ ID NO: 6 or 7.

4 . The prodrug of claim 1 , further comprising a second cytokine moiety, wherein the second cytokine moiety comprises

(i) a human IL-2 agonist polypeptide comprising SEQ ID NO: 8,

(ii) a human IL-7 agonist polypeptide comprising SEQ ID NO: 28,

(iii) a human IL-9 agonist polypeptide comprising wildtype human IL-9 polypeptide,

(iv) a human IL-15 agonist polypeptide comprising SEQ ID NO: 9,

(v) a human IL-15 agonist polypeptide and a human IL-15 receptor alpha sushi domain, or

(vi) a human CCL19 polypeptide comprising SEQ ID NO: 27.

5 . The prodrug of claim 4 , further comprising a second masking moiety that binds to the second cytokine moiety and inhibits a biological activity of the second cytokine moiety, wherein the second masking moiety is fused to the second cytokine moiety or to the carrier moiety through a cleavable peptide linker, and wherein the second masking moiety comprises an ECD of IL-2 receptor beta subunit, an ECD of an IL-7 receptor, or an ECD of an IL-9 receptor.

6 . The prodrug of claim 4 , wherein the human IL-21 agonist polypeptide and/or the second cytokine moiety is fused to the carrier moiety through a noncleavable peptide linker.

7 . The prodrug of claim 6 , wherein the noncleavable peptide linker comprises an amino acid sequence selected from SEQ ID NOs: 29-33.

8 . The prodrug of claim 1 , wherein the cleavable peptide linker comprises a substrate sequence of urokinase-type plasminogen activator (uPA), matrix metallopeptidase (MMP) 2, or MMP9.

9 . The prodrug of claim 8 , wherein the cleavable peptide linker comprises substrate sequences of (i) both uPA and MMP2, (ii) both uPA and MMP9, or (iii) uPA, MMP2 and MMP9.

10 . The prodrug of claim 8 , wherein the cleavable peptide linker comprises an amino acid sequence selected from SEQ ID NOs: 11-26.

11 . The prodrug of claim 1 , wherein the cleavable peptide linker is cleavable by one or more proteases located at a tumor site or its surrounding environment, and the cleavage leads to activation of the prodrug at the tumor site or surrounding environment.

12 . The prodrug of claim 1 , wherein the carrier moiety is a PEG molecule, an albumin, an albumin fragment, an antibody Fc domain, or an antibody or an antigen-binding fragment thereof.

13 . The prodrug of claim 12 , wherein the carrier moiety is an antibody Fc domain or an antibody that comprises L234A and L235A (“LALA”) mutations (EU numbering).

14 . The prodrug of claim 12 , wherein the carrier moiety is an antibody Fc domain or an antibody comprising knobs-into-holes mutations, and wherein

the human IL-21 agonist polypeptide and its masking moiety are fused to different polypeptide chains of the antibody Fc domain or to the different heavy chains of the antibody, and optionally further comprising a second cytokine moiety and second masking moiety, wherein

the second cytokine moiety and the second masking moiety also are fused to different polypeptide chains of the antibody Fc domain or to the different heavy chains of the antibody.

15 . The prodrug of claim 14 , wherein the human IL-21 agonist polypeptide and its masking moiety are fused to the C-termini of the two different polypeptide chains of the Fc domain or to the C-termini of the two different heavy chains of the antibody.

16 . The prodrug of claim 14 , wherein the human IL-21 agonist polypeptide and its masking moiety are fused to the N-termini of the two different polypeptide chains of the Fc domain or to the N-termini of the two different heavy chains of the antibody.

17 . The prodrug of claim 14 , wherein the second cytokine moiety and the second masking moiety are fused to the opposite termini of the two different polypeptide chains of the Fc domain, or to the opposite termini of the two different heavy chains of the antibody, from the human IL-21 agonist polypeptide and its masking moiety.

18 . The prodrug of claim 14 , wherein the knobs-into-holes mutations comprise a T366Y “knob” mutation on a polypeptide chain of the Fc domain or a heavy chain of the antibody, and a Y407T “hole” mutation in the other polypeptide of the Fc domain or the other heavy chain of the antibody (EU numbering).

19 . The prodrug of claim 14 , wherein the knobs-into-holes mutations comprise Y349C and/or T366W mutations in the CH3 domain of the “knob chain” and E356C, T366S, L368A, and/or Y407V mutations in the CH3 domain of the “hole chain” (EU numbering).

20 . The prodrug of claim 14 , wherein said prodrug comprises two polypeptide chains whose amino acid sequences respectively comprise

SEQ ID NOs: 36 and 38,

SEQ ID NOs: 37 and 38,

SEQ ID NOs: 39 and 41, or

SEQ ID NOs: 40 and 41.

21 . The prodrug of claim 12 , wherein the carrier moiety is an antibody or an antigen-binding fragment thereof that specifically binds to one or more antigens selected from Guanyl cyclase C (GCC), carbohydrate antigen 19-9 (CA19-9), glycoprotein A33 (gpA33), mucin 1 (MUC1), carcinoembryonic antigen (CEA), insulin-like growth factor 1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), delta-like protein 3 (DLL3), delta-like protein 4 (DLL4), epidermal growth factor receptor (EGFR), glypican-3 (GPC3), c-MET, vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), Nectin-4, Liv-1, glycoprotein NMB (GPNMB), prostate specific membrane antigen (PSMA), Trop-2, carbonic anhydrase IX (CA9), endothelin B receptor (ETBR), six transmembrane epithelial antigen of the prostate 1 (STEAP1), folate receptor alpha (FR-α), SLIT and NTRK-like protein 6 (SLITRK6), carbonic anhydrase VI (CA6), ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), mesothelin, trophoblast glycoprotein (TPBG), CD19, CD20, CD22, CD33, CD40, CD56, CD66e, CD70, CD74, CD79b, CD98, CD123, CD138, CD352, CD47, signal- regulatory protein alpha (SIRPα), PD1, Claudin 18.2, Claudin 6, 5T4, BCMA, PD-L1, PD-1, Fibroblast Activation Protein alpha (FAPalpha), the Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), and EPCAM.

22 . The prodrug of claim 12 , comprising two heavy chain polypeptides whose amino acid sequences comprise SEQ ID NOs: 48 and 49, respectively; and a light chain comprises SEQ ID NO: 50 or 51.

23 . A pharmaceutical composition comprising the prodrug of claim 1 and a pharmaceutically acceptable excipient.

24 . A method of treating a cancer or an infectious disease, or stimulating the immune system, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 23 .

25 . The method of claim 24 , wherein the patient has HIV, HBV, HCV, or HPV infection; or a cancer selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, esophageal cancer, medullary thyroid cancer, ovarian cancer, uterine cancer, prostate cancer, testicular cancer, colorectal cancer, and stomach cancer.

Assignments (1)

Continuity (2)

References Cited (235)